



## Could the NNH really be 28?

### Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta-analysis<sup>1</sup>

#### Findings at a glance

- ◆ In 14 randomized placebo controlled trials with 8216 participants, varenicline was associated with an increase in serious adverse CV events.
  - **Varenicline vs Placebo – CV events:** **52/4908 vs 27/3308**  
**1.06% vs 0.82%**
  - **Peto Odds Ratio (OR):** **1.72; 95% CI=1.09-2.71**
    - CV events included: MI, unstable angina, coronary revascularization, coronary artery disease, arrhythmias, transient ischemic attacks, stroke, sudden death/CV death, congestive heart failure
    - Role of adjudication for events: unclear (CV events never part of 1° endpoint; thus rely on 2° endpoint data); ∴ caution
    - Treatment duration: 7 days – 12 weeks. Duration of total follow-up: 24-52 weeks.
    - Risk of bias: low 9 trials; unclear 5 trials. Sensitivity analysis: supportive of findings
    - A standard OR calculation (as opposed to the Peto OR method used) results in an **OR=1.3** (95% CI 0.82-2.08)<sup>2</sup>

#### Questions about the extrapolated Number Needed to Harm (NNH) = 28

- ◆ Authors extrapolate the Peto OR to a population of smokers with stable CV disease:
  - **NNH=28** 52 weeks of follow up for 12 weeks of therapy; from authors' discussion  
(For every 28 patients treated with varenicline vs placebo, there is 1 extra serious CV event)
  - To get this NNH, the authors applied the OR to a baseline risk of 5.57% per 52 weeks<sup>3</sup>
    - The resulting projected CV event risk for varenicline vs placebo rounded off
      - $\cong 9.6\%$  ( $1.72 \times 5.6\%$ ) vs 5.6%
      - Absolute risk  $\uparrow \cong 4\%$ ; NNH  $\cong 25$  100/4%; on  $\leq 1$  year follow up of 1 treatment course
- ◆ CAUTION: There are some problems with this extrapolation
  - The actual meta-analysis only had an absolute risk increase of 0.24% (1.06% vs 0.82%)
    - Resulting **NNH would be 417** 100/0.24% overall for patients in trials
  - The baseline risk for smokers with stable CV disease was taken from the one trial that included this population.<sup>4</sup> However, in this trial the absolute risk only went up 1.4% (CV events: 7.1% vs 5.7%; OR=1.28 (0.7-2.34), not significant. Had the results been significant, the NNH would have been around 72). Of interest, this one trial was weighted to account for 57% of all CV events in the meta-analysis. {The OR =1.28 in this highest weighted study of CV disease patients is consistent with a non-Peto OR method =1.3 in the meta.}

#### Bottom Line – from our point of view

- ◆ Systematic review/meta-analysis was well done and provides hypothesis generating evidence for a **potential small increase in CV risk** with varenicline versus placebo within 1 year follow up of treatment.
- ◆ The extrapolated NNH=28 for CV risk in smokers with stable CV disease is quite questionable and may overstate the risk. Meta-analysis techniques can vary and may be open to criticism.
- ◆ One final over-riding point. Many patients stop smoking without the help of drug therapy. For those who may need a drug to stop, the benefit of stopping, especially long-term, is usually thought to outweigh the risks. Other pharmacotherapy alternatives<sup>5,6</sup>, all with their own risk benefit profiles, include nicotine replacement therapy e.g. NICODERM, HABITROL, NICORETTE, THRIVE, bupropion ZYBAN and nortriptyline AVENTYL.
- ◆ If you will indulge me for a moment, I'd suggest one slightly humorous way to look at the results. ☺

*In 14 trials that analysed 8216 patients on varenicline vs placebo, the NNH was 417. In 0 trials analysing 0 patients, but all of whom were at much higher risk, this extrapolated NNH would be 28, assuming that the proposed odds ratio holds true. Note that the absolute risk of continuing smoking would also be a major factor to consider in weighing the risk/benefit of therapy.*

Prepared by Loren Regier BSP BA., Brent Jensen BSP, Michael Hewitt for RxFiles. July 2011.  
Thanks also to Margaret Jin PharmD and JinHui Ma PhD (Stats) for assistance in the review process.

Copyright 2011 RxFiles, Saskatoon Health Region; All Rights Reserved. DISCLAIMER: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of SHR. Neither the authors nor SHR nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources.

## Extras:

### RxFiles Meta Q&A – July 2011:


**Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix, Chantix):  
Comment on Systematic Review and Meta-analysis**

FDA Drug Safety Communication link (Aug 2011): <http://www.fda.gov/Drugs/DrugSafety/ucm264436.htm>

## References

- <sup>1</sup> Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011 Jul 4.
- <sup>2</sup> Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of Interventions* - Combining Studies. {Online discussion of Peto vs Mantel-Haenszel OR methods in meta-analysis.} Accessed at <http://www.cochrane-net.org/openlearning/html/mod12-3.htm> . Accessed online 13 July, 2011.
- <sup>3</sup> **Calculation of NNT from OR:**  
$$\text{NNT} = ((\text{PEER} * (\text{OR} - 1)) + 1) / (\text{PEER} * (\text{OR} - 1) * (1 - \text{PEER}))$$
$$= ((0.0557 * (1.72 - 1)) + 1) / (0.0557 * (1.72 - 1) * (1 - 0.0557))$$
$$= 27.46$$

Let OR=1.09, NNT= 12.18  
Let OR=2.71, NNT= 212.31
- <sup>4</sup> Rigotti NA, Pipe AL, Benowitz NL, Artega C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation*. 2010 Jan 19;121(2):221-9.
- <sup>5</sup> Regier L, Jensen B, Chan W. Tobacco / Smoking Cessation Pharmacotherapy Chart. RxFiles Drug Comparison Charts. 8<sup>th</sup> Ed. Saskatoon, SK: Saskatoon Health Region; 2010. Available from: <http://www.rxfiles.ca/rxfiles/uploads/documents/members/CHT-Smoking-Cessation.pdf> . Accessed online 12 July, 2011.
- <sup>6</sup> Regier L, Jensen B. Smoking Cessation Pharmacotherapy. RxFiles. Saskatoon, SK: Saskatoon Health Region; Oct 2006. Available from: <http://www.rxfiles.ca/rxfiles/uploads/documents/Smoking-Cessation-Newsletter-Header.pdf> . Accessed online July 12, 2011.



For more information about us, see [RxFiles.ca](http://RxFiles.ca)

RxFiles Drug Comparison Charts Book 8<sup>th</sup> Edition  
RxFiles, c/o Saskatoon City Hospital, 701 Queen Street, Saskatoon, SK. S7K 0M7;  
Online: [www.RxFiles.ca](http://www.RxFiles.ca)